Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard therapy for advanced NSCLC patients with EGFR‐activated mutations based on some famous phase III trials 9, 10, 11. This evidence concerns the gene EGFR and non-small cell lung carcinoma.